The current state of DDS for respiratory tract infection

DOI Web Site 2 Citations 19 References
  • Yanagihara Katsunori
    Second Department of Internal Medicine, Nagasaki University Graduate School of Medical Sciences Department of Laboratory Medicine, Nagasaki University Graduate School of Medical Sciences
  • Kohno Shigeru
    Second Department of Internal Medicine, Nagasaki University Graduate School of Medical Sciences

Bibliographic Information

Other Title
  • 呼吸器感染症治療におけるＤＤＳの現況
  • コキュウキ カンセンショウ チリョウ ニ オケル DDS ノ ゲンキョウ

Search this article

Abstract

According to the Japanese Ministry of Health, Labour and Welfare (MHLW), pneumonia is the fourth leading cause of death in Japan. Respiratory tract infection such as pneumonia is important for the elderly patients. Thus, the development of DDS with the aim of reducing the frequency of dosing and improving compliance is also suggestive of a new trend for DDS in the field of treating Respiratory tract infection.<BR>Azithromycin-SR will be released as the choice for community-acquired pneumonia in near future. Liposomal amphotericin B for empirical therapy in patients with deep seated mycosis is useful for clinicians. Inhaled amikacin and the new pulmonary drug delivery system have been expected as the new treatment for the patients infected with resistant bacteria.

Journal

  • Drug Delivery System

    Drug Delivery System 23 (4), 448-453, 2008

    THE JAPAN SOCIETY OF DRUG DELIVERY SYSTEM

Citations (2)*help

See more

References(19)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top